Dibucaine

Structural formula
General
Non-proprietary name	Cinchocaine
other names	2-butoxy- N - (2-diethylaminoethyl) -quinoline-4-carbamide ( IUPAC )
Molecular formula	C 20 H 29 N 3 O 2
External identifiers / databases
CAS number 85-79-0 EC number 201-632-1 ECHA InfoCard 100.001.484 PubChem 3025 ChemSpider 2917 DrugBank DB00527 Wikidata Q417603
Drug information
ATC code	C05 AD04 D04 AB02 N01 BB06 S01 HA06
Drug class	Local anesthetic
properties
Molar mass	343.46 g · mol -1
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS labeling of hazardous substances danger H and P phrases H: 302-318 P: 280-305 + 351 + 338
Toxicological data	24.5 mg kg −1 ( LD 50 ,  mouse ,  ip )
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Dibucaine ( cinchocaine ) is a local anesthetic of the amide type. As one of the first of its kind, it was synthesized around 1930. In 1931 the active ingredient was patented by CIBA AG . Today, dibucain is particularly important in laboratory diagnostics and in the treatment of inflammatory diseases of the anus. It has a slow onset of action and a duration of approx. 1.5–2 hours. As a surface anesthetic, it is 100 times more effective than cocaine . The toxicity is also quite great; it is 15-20 times the toxicity of the relatively less toxic procaine .

Pharmacokinetics

Dibucaine can be absorbed through the skin. The active ingredient is broken down in the liver and excreted in the urine.

application areas

• As a substrate for pseudocholinesterase , dibucaine is used in the laboratory diagnostics of atypical forms of this enzyme . In the dibucaine test introduced in 1957 by W. Kalow and K. Genest, the so-called dibucaine number provides information about the activity of pseudocholinesterase after the addition of dibucaine.
• In combination with other active ingredients (for example in Otobacid : dexamethasone , cinchocaine hydrochloride and butane-1,3-diol ), dibucaine is used in various areas of medicine - for example in ear, nose and throat medicine  - as a locally acting anesthetic .

Trade names

Monopreparations

DoloPosterine (D)

Combination preparations

Decatylen Neo (CH), Faktu (D, CH), Locaseptil (CH), Otobacid (D), Scheriproct (A, CH)

Individual evidence

1. ↑ ^{a b} Dibucaine data sheet at Sigma-Aldrich , accessed on November 6, 2016 ( PDF ).
2. ↑ Entry on dibucain in the ChemIDplus database of the United States National Library of Medicine (NLM) .
3. ↑ Entry on cinchocaine. In: Römpp Online . Georg Thieme Verlag, accessed on January 24, 2019.
4. ↑ Eberhard Schröder, Clemens Rufer, Ralph Schmiechen, Arzneimittelchemie I, Georg Thieme Verlag 1976 ISBN 3-13-520601-7
5. ↑ Michael Heck, Michael Fresenius: Repetitorium Anaesthesiologie. Preparation for the anesthesiological specialist examination and the European diploma in anesthesiology. 3rd, completely revised edition. Springer, Berlin / Heidelberg / New York et al. 2001, ISBN 3-540-67331-8 , p. 804.
6. ↑ Landessozialgericht Berlin-Brandenburg: L 7 KA 11/10 KL ER . Retrieved November 20, 2010.
7. ↑ Red List online, as of October 2009.
8. ↑ AM comp. d. Switzerland, as of October 2009.
9. ↑ AGES-PharmMed, as of October 2009.

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !